CPIX Strangle Strategy

CPIX (Cumberland Pharmaceuticals Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CPIX (Cumberland Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $72.7M, a beta of -0.06 versus the broader market, a 52-week range of 1.85-6.27, average daily share volume of 1.0M, a public-listing history dating back to 2009, approximately 91 full-time employees. These structural characteristics shape how CPIX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.06 indicates CPIX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on CPIX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current CPIX snapshot

As of May 15, 2026, spot at $5.41, ATM IV 140.90%, IV rank 38.27%, expected move 40.39%. The strangle on CPIX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on CPIX specifically: CPIX IV at 140.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 40.39% (roughly $2.19 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CPIX expiries trade a higher absolute premium for lower per-day decay. Position sizing on CPIX should anchor to the underlying notional of $5.41 per share and to the trader's directional view on CPIX stock.

CPIX strangle setup

The CPIX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CPIX near $5.41, the first option leg uses a $5.68 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CPIX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CPIX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$5.68N/A
Buy 1Put$5.14N/A

CPIX strangle risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

CPIX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on CPIX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on CPIX

Strangles on CPIX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CPIX chain.

CPIX thesis for this strangle

The market-implied 1-standard-deviation range for CPIX extends from approximately $3.22 on the downside to $7.60 on the upside. A CPIX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CPIX IV rank near 38.27% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on CPIX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, CPIX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CPIX-specific events.

CPIX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CPIX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CPIX alongside the broader basket even when CPIX-specific fundamentals are unchanged. Always rebuild the position from current CPIX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on CPIX?
A strangle on CPIX is the strangle strategy applied to CPIX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CPIX stock trading near $5.41, the strikes shown on this page are snapped to the nearest listed CPIX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are CPIX strangle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CPIX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 140.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CPIX strangle?
The breakeven for the CPIX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CPIX market-implied 1-standard-deviation expected move is approximately 40.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on CPIX?
Strangles on CPIX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CPIX chain.
How does current CPIX implied volatility affect this strangle?
CPIX ATM IV is at 140.90% with IV rank near 38.27%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related CPIX analysis